{"id":62124,"date":"2025-10-31T19:02:40","date_gmt":"2025-10-31T18:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/"},"modified":"2025-10-31T19:02:40","modified_gmt":"2025-10-31T18:02:40","slug":"appointment-of-yves-decadt-as-member-of-poxels-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/","title":{"rendered":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–Regulatory News:<\/p>\n

<\/a>
<\/a><\/p>\n

\nPOXEL SA<\/a> (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.<\/p>\n

\nFollowing the governance changes implemented on July 31, this appointment further strengthens Poxel\u2019s strategic and commercial organization. It will be submitted for shareholder approval at the Company\u2019s next Annual General Meeting.<\/p>\n

\nYves Decadt brings over 25 years of international experience in the pharmaceutical industry. He spent nearly 20 years at Johnson & Johnson within the Global Business Development department, where he was responsible for licensing and deal negotiations, particularly across Asia. He has also held several senior executive positions in leading biopharma and medtech companies. Yves will bring to Poxel a unique combination of scientific and strategic expertise, as well as access to an extensive global network. Since August 2025, Yves has been working with Poxel\u2019s teams under a consultancy agreement, supporting ongoing partnership discussions and conducting an in-depth assessment of the commercial development potential of Poxel\u2019s main assets.<\/p>\n

\nYves Decadt holds degrees in Bio-Engineering and Industrial Business Administration from University of Ghent (Vlerick School), as well as in Pharmacology and Pharmaceutical Medicine from the Universit\u00e9 Libre de Bruxelles. He also holds a Board Director Certification from Duke University.<\/p>\n

\nIn order to comply with gender balance requirements applicable to Poxel\u2019s Board of Directors, which currently comprises fewer than eight members, it was agreed that the implementation of Yves Decadt\u2019s appointment would entail the prior resignation of Nicolas Trouche from his position as Director. This ensures compliance with the minimum gender representation required by law.<\/p>\n

\nNicolas Trouche, Chief Executive Officer of Poxel<\/b>, stated: <\/b>\u201cWe are delighted to propose the appointment of Yves Decadt to Poxel\u2019s Board of Directors. His expertise and proven track record in developing strategic partnerships will be invaluable in strengthening and accelerating value creation for Poxel and its stakeholders, while continuing to enhance the value of our product portfolio.\u201d<\/i><\/p>\n

\nAbout Poxel SA<\/b><\/p>\n

\nPoxel is a clinical stage biopharmaceutical company<\/b> developing innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including metabolic dysfunction-associated steatohepatitis (MASH)<\/b> and rare disorders. For the treatment of MASH, PXL065<\/b> (deuterium-stabilized R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.<\/p>\n

\nFor more information, please visit: www.poxelpharma.com<\/a><\/p>\n

\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor relations \/ Media<\/b>
NewCap
\n
Aur\u00e9lie Manavarere, Th\u00e9o Martin \/ Arthur Rouill\u00e9
\n
investors@poxelpharma.com<\/a>
+33 1 44 71 94 94<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors. Following the governance changes implemented … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62124","6":"format-standard","7":"category-industry"},"yoast_head":"\nAppointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors. Following the governance changes implemented ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T18:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors\",\"datePublished\":\"2025-10-31T18:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/\"},\"wordCount\":661,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251031569100\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/\",\"name\":\"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251031569100\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"datePublished\":\"2025-10-31T18:02:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251031569100\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251031569100\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors. Following the governance changes implemented ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-31T18:02:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors","datePublished":"2025-10-31T18:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/"},"wordCount":661,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/","name":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg","datePublished":"2025-10-31T18:02:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251031569100\/en\/729490\/22\/POXEL_LOGO_Q.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Appointment of Yves Decadt as Member of Poxel\u2019s Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62124"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62124\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}